Liver X receptor-mediated gene regulation and cholesterol homeostasis in brain: Relevance to Alzheimer's disease therapeutics

Current Alzheimer Research

Volumn 4, Issue 2, 2007, Pages 179-184

  Cao, Guoqing ^a   Bales, Kelly R ^a   DeMattos, Ronald B ^a   Paul, Steven M ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

ABCA1; Amyloid; Apolipoprotein E; Cholesterol; Glia; Nuclear hormone receptors

Indexed keywords

3 [3 [[2 CHLORO 3 (TRIFLUOROMETHYL)BENZYL](2 DIPHENYLETHYL)AMINO]PROPOXY]PHENYLACETIC ACID; ABC TRANSPORTER A1; AMYLOID BETA PROTEIN; APOLIPOPROTEIN C; APOLIPOPROTEIN E; HORMONE RECEPTOR STIMULATING AGENT; LIVER X RECEPTOR; LIVER X RECEPTOR AGONIST; N (2,2,2 TRIFLUOROETHYL) N [4 [2,2,2 TRIFLUORO 1 HYDROXY 1 (TRIFLUOROMETHOXY)ETHYL]PHENYL]BENZENESULFONAMIDE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ASTROCYTE; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; DRUG MECHANISM; GENE CONTROL; HOMEOSTASIS; MICROGLIA; NONHUMAN; PLAQUE FORMING CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; REVIEW;

ANIMALS; BRAIN; CHOLESTEROL; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION; HOMEOSTASIS; HUMANS; METABOLIC NETWORKS AND PATHWAYS; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 34147131740     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720507780362173     Document Type: Review

References (77)

1. Abildayeva K, Jansen PJ, Hirsch-Reinshagen V, Bloks VW, Bakker AH, Ramaekers, et al. 24 (S)-hydroxycholesterol participates in a liver X receptor-controlled pathway in astrocytes that regulates apolipoprotein E-mediated cholesterol efflux. J Biol Chem 281 (2006) 12799-808.
2. Bales KR, Verina T, Cummins DJ, Du Y, Dodel RC, Saura J, et al. Apolipoprotein E is essential for amyloid deposition in the APP (V717F) transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 96: 15233-8 (1999).
3. Bales KR, Verina T, Dodel RC, Du Y, Altstiel L, Bender M, et al. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet 17: 263-4 (1997).
4. Bodovitz S and Klein WL. Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein. J Biol Chem 271: 4436-40 (1996).
5. Brooks-Wilson A, Marcil M, Clee SM, Zhang LH, Roomp K, van Dam M, et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency, Nat Genet 22: 336-45 (1999).
6. Buxbaum JD, Geoghagen NS and Friedhoff LT. Cholesterol depletion with physiological concentrations of a statin decreases the formation of the Alzheimer amyloid Abeta peptide. J Alzheimers Dis 3: 221-229 (2001).
7. Cao G, Beyer TP, Yang XP, Schmidt RJ, Zhang Y, Bensch WR, et al. Phospholipid transfer protein is regulated by liver x receptors in vivo. J Biol Chem 277: 39561-5 (2002).
8. Collins JL, Fivush AM, Watson MA, Galardi CM, Lewis MC, Moore LB, et al. Identification of a nonsteroidal liver X receptor agonist through parallel array synthesis of tertiary amines. J Med Chem 45: 1963-6 (2002).
9. Costet P, Luo Y, Wang N and Tall AR Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J Biol Chem 275: 28240-5 (2000).
10. DeMattos RB, P.M., O'Dell MA, Taylor JW, Bales KR, Paul SM, Holtzman DM, Apolipoprotein E3 dose dependent modulation of Amyloid-beta deposition in a transgenic mouse model of Alzheimer's disease., Society of Neuroscience Abstract, 32 (2002) 723.
11. Dietschy JM and Turley SD. Cholesterol metabolism in the brain. Curr Opin Lipidol 12: 105-12 (2001).
12. Fagan AM, Christopher E, Taylor JW, Parsadanian M, Spinner M, Watson M, et al. ApoAI deficiency results in marked reductions in plasma cholesterol but no alterations in amyloid-beta pathology in a mouse model of Alzheimer's disease-like cerebral amyloidosis. Am J Pathol 165: 1413-22 (2004).
13. Fagan AM, Holtzman DM, Munson G, Mathur T, Schneider D, Chang LK, et al. Unique lipoproteins secreted by primary astrocytes from wild type, apoE (-/-), and human apoE transgenic mice, J Biol Chem 274: 30001-7 (1999).
14. Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, et al. Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci USA 98: 5856-61 (2001).
15. Fu X, Menke JG, Chen Y, Zhou G, MacNaul KL, Wright SD, et al.27-hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells. J Biol Chem 276: 38378-87 (2001).
16. Fukumoto H, Deng A, Irizarry MC, Fitzgerald ML and Rebeck GW. Induction of the cholesterol transporter ABCA1 in central nervous system cells by liver X receptor agonists increases secreted Abeta levels. J Biol Chem 277: 48508-13 (2002).
17. Hallman DM, Boerwinkle E, Saha N, Sandholzer C, Menzel HJ, Csazar A, et al. The apolipoprotein E polymorphism: a comparison of allele frequencies and effects in nine populations. Am J Hum Genet 49: 338-49 (1991).
18. Hardy J and Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-6 (2002).
19. Hirsch-Reinshagen V, Maia LF, Burgess BL, Blain JF, Naus KE, McIsaac SA, et al. The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease. J Biol Chem 280: 43243-56 (2005).
20. Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 97: 2892-7 (2000).
21. Holtzman DM, Bales KR, Wu S, Bhat P, Parsadanian M, Fagan AM, et al. Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer's disease, J Clin Invest 103 R15-R21 (1999).
22. Hummasti S, Laffitte BA, Watson MA, Galardi C, Chao LC, Ramamurthy L, et al. Liver X receptors are regulators of adipocyte gene expression but not differentiation: identification of apoD as a direct target. J Lipid Res 45: 616-25 (2004).
23. Janowski BA, Grogan MJ, Jones SA, Wisely GB, Kliewer SA, Corey EJ, et al. Structural requirements of ligands for the oxysterol liver X receptors LXRalpha and LXRbeta. Proc Natl Acad Sci USA 96 266-71 (1999).
24. Janowski BA, Willy PJ, Devi TR, Falck JR and Mangelsdorf DJ. An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature 383: 728-31 (1996).
25. Jarvik GP, Wijsman EM, Kukull WA, Schellenberg GD, Yu C and Larson EB. Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study. Neurology 45: 1092-6 (1995).
26. Jick H, Zornberg GL, Jick SS, Seshadri S and Drachman DA. Statins and the risk of dementia. Lancet 356: 1627-31 (2000).
27. Kalmijn S, Launer LJ, Ott A, Witteman JC, Hofman A and Breteler MM. Dietary fat intake and the risk of incident dementia in the Rotterdam Study. Ann Neurol 42: 776-82 (1997).
28. Kennedy MA, Venkateswaran A, Tarr PT, Xenarios I, Kudoh J, Shimizu N, et al. Characterization of the human ABCG1 gene: liver X receptor activates an internal promoter that produces a novel transcript encoding an alternative form of the protein. J Biol Chem 276: 39438-47 (2001).
29. Koistinaho M, Lin S, Wu X, Esterman M, Koger D, Hanson J, et al, Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nat Med 10 (2004) 719-26.
30. Kojro E, Gimpl G, Lammich S, Marz W and Fahrenholz F. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha -secretase ADAM 10. Proc Natl Acad Sci USA 98: 5815-20 (2001).
31. Koldamova R, Staufenbiel M and Lefterov I. Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice. J Biol Chem 280: 43224-35. (2005).
32. Koldamova RP, Lefterov IM, Ikonomovic MD, Skoko J, Lefterov PI, Isanski BA, et al. 22R-Hydroxycholesterol and 9-cis-retinoic acid induce ABCA1 transporter expression and cholesterol efflux in brain cells and decrease Abeta secretion. J Biol Chem 22: 22 (2003).
33. Koldamova RP, Lefterov IM, Staufenbiel M, Wolfe D, Huang S, Glorioso JC, et al. The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease. J Biol Chem 280: 4079-88 (2005).
34. Kotti TJ, Ramirez DM, Pfeiffer BE, Huber KM and Russell DW. Brain cholesterol turnover required for geranylgeraniol production and learning in mice. Proc Natl Acad Sci USA 103: 3869-74. (2006) Epub 2006 Feb 27.
35. Kuo YM, Emmerling MR, Bisgaier CL, Essenburg AD, Lampert HC, Drumm D. et al. Elevated low-density lipoprotein in Alzheimer's disease correlates with brain abeta 1-42 levels. Biochem Biophys Res Commun 252: 711-5 (1998).
36. Ladu MJ, Reardon C, Van Eldik L, Fagan AM, Bu G, Holtzman D, et al. Lipoproteins in the central nervous system. Ann NY Acad Sci 903: 167-75 (2000).
37. Laffitte BA, Repa JJ, Joseph SB, Wilpitz DC, Kast HR, Mangelsdorf, DJ, et al. LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proc Natl Acad Sci USA 98: 507-12 (2001).
38. Lawn RM, Wade DP, Couse TL and Wilcox JN. Localization of human ATP-binding cassette transporter 1 (ABC1) in normal and atherosclerotic tissues. Arterioscler Thromb Vasc Biol 21: 378-85 (2001).
39. Lawn RM, Wade DP, Garvin MR, Wang X, Schwartz K, Porter JG, et al. The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. J Clin Invest 104: R25-31 (1999).
40. Li G, Higdon R, Kukull WA, Peskind E, Van Valen Moore K, Tsuang D, et al. Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. Neurology 63: 1624-8 (2004).
41. Liang Y, Jiang XC, Liu R, Liang G, Beyer TP, Gao H, et al. Liver X receptors (LXRs) regulate apolipoprotein AIV-implications of the antiatherosclerotic effect of LXR agonists. Mol Endocrinol 18: 2000-10 (2004). Epub 2004 May 6.
42. Liang Y, Lin S, Beyer TP, Zhang Y, Wu X, Bales KR, et al. A liver X receptor and retinoid X receptor heterodimer mediates apolipoprotein E expression, secretion and cholesterol homeostasis in astrocytes. J Neurochem 88: 623-34 (2004).
43. Lu TT, Repa JJ and Mangelsdorf DJ. Orphan nuclear receptors as eLiXiRs and FiXeRs of sterol metabolism. J Biol Chem 276: 37735-8 (2001).
44. Lund EG, Guileyardo JM and Russell DW. cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain. Proc Natl Acad Sci USA 96: 7238-43 (1999).
45. Lund EG, Xie C, Kotti T, Turley SD, Dietschy JM. and Russell DW. Knockout of the cholesterol 24-hydroxylase gene in mice reveals a brain-specific mechanism of cholesterol turnover. J Biol Chem 278: 22980-8 (2003).
46. Luo Y and Tall AR. Sterol upregulation of human CETP expression in vitro and in transgenic mice by an LXR element. J Clin Invest 105 513-20 (2000).
47. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 240: 622-30 (1988).
48. Mak PA, Kast-Woelbern HR, Anisfeld AM and Edwards PA. Identification of PLTP as an LXR target gene and apoE as an FXR target gene reveals overlapping targets for the two nuclear receptors. J Lipid Res 43: 2037-41. (2002)
49. Mak PA, Laffitte BA, Desrumaux C, Joseph SB, Curtiss LK, Mangelsdorf DJ, et al. Regulated expression of the ApoE/C-I/C-IV/C-II gene cluster in murine and human macrophages; A critical role for the nuclear receptors LXRalpha and LXRbeta. J Biol Chem 24:24 (2002).
50. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, et al. The nuclear receptor superfamily: the second decade. Cell 83 835-9 (1995).
51. McNeish J, Aiello RJ, Guyot D, Turi T, Gabel C, Aldinger C, et al. High density lipoprotein deficiency and foam cell accumulation in mice with targeted disruption of ATP-binding cassette transporter-1. Proc Natl Acad Sci USA 97: 4245-50 (2000).
52. Michikawa M, Fan QW, Isobe I and Yanagisawa K. Apolipoprotein E exhibits isoform-specific promotion of lipid efflux from astrocytes and neurons in culture, J Neurochem, 74: 1008-16 (2000).
53. Notkola IL, Sulkava R, Pekkanen J, Erkinjuntti T, Ehnholm C, Kivinen P, et al. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology 17: 14-20 (1998).
54. Orso E, Broccardo C, Kaminski WE, Bottcher A, Liebisch G, Drobnik W, et al. Transport of lipids from golgi to plasma membrane is defective in tangier disease patients and Abc1-deficient mice. Nat Genet 24: 192-6 (2000).
55. Peet DJ, Turley SD, Ma W, Janowski BA, Lobaccaro JM, Hammer RE, et al. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell 93: 693-704 (1998).
56. Repa JJ, Berge KE, Pomajzl C, Richardson JA, Hobbs HH. and Mangelsdorf, D.J., Regulation of ATP-binding cassette sterol transporters, ABCG5 and ABCG8, by the oxysterol receptors, LXRalpha and beta. J Biol Chem 18: 18 (2002).
57. Romas SN, Tang MX, Berglund L and Mayeux R. APOE genotype, plasma lipids, lipoproteins, and AD in community elderly. Neurology 53: 517-21 (1999).
58. Ruiz J, Kouiavskaia D, Migliorini M, Robinson S, Saenko EL, Gorlatova N, et al. The apoE isoform binding properties of the VLDL receptor reveal marked differences from LRP and the LDL receptor. J Lipid Res 46: 1721-31 (2005).
59. Schultz JR, Tu H, Luk A, Repa JJ, Medina JC, Li L, et al. Role of LXRs in control of lipogenesis. Genes Dev 14: 2831-8 (2000).
60. Shinar DM, Endo N, Rutledge SJ, Vogel R, Rodan GA and Schmidt A. NER, a new member of the gene family encoding the human steroid hormone nuclear receptor. Gene 147: 273-6 (1994).
61. Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG and Simons K. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci USA 95: 6460-4 (1998).
62. Simons M, Schwarzler F, Lutjohann D, von Bergmann K, Beyreuther K, Dichgans J, et al. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol 52: 346-50 (2002).
63. Song C, Hiipakka RA, Kokontis JM and Liao S. Ubiquitous receptor: structures, immunocytochemical localization, and modulation of gene activation by receptors for retinoic acids and thyroid hormones. Ann NY Acad Sci 761: 38-49 (1995).
64. Sparks DL, Sabbagh MN, Connor DJ, Lopez J, Launer LJ, Browne P, et al. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol 62: 753-7 (2005).
65. Strittmatter WJ and Roses AD. Apolipoprotein E and Alzheimer disease. Proc Natl Acad Sci USA 92: 4725-7 (1995).
66. Strittmatter WJ, Weisgraber KH, Huang DY, Dong LM, Salvesen GS, Pericak-Vance M, et al. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci USA 90: 8098-102 (1993).
67. Sun Y, Yao J, Kim TW and Tall AR. Expression of LXR target genes decreases cellular amyloid beta peptide secretion. J Biol Chem 16: 16 (2003).
68. Teboul M, Enmark E, Li Q, Wikstrom AC, Pelto-Huikko M and Gustafsson JA. OR-1, a member of the nuclear receptor superfamily that interacts with the 9-cis-retinoic acid receptor. Proc Natl Acad Sci USA 92: 2096-100 (1995).
69. Von Eckardstein A, Langer C, Engel T, Schaukal I, Cignarella A, Reinhardt J, et al. ATP binding cassette transporter ABCA1 modulates the secretion of apolipoprotein E from human monocyte-derived macrophages. FASEB J 15: 1555-61 (2001).
70. Wahrle SE, Jiang H, Parsadanian M, Hartman RE, Bales KR, Paul SM, et al. Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease. J Biol Chem 280: 43236-42 (2005).
71. Wahrle SE, Jiang H, Parsadanian M, Legleiter J, Han X, Fryer JD, et al. ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE. J Biol Chem 279: 40987-93 (2004).
72. Wang L, Schuster GU, Hultenby K, Zhang Q, Andersson S and Gustafsson JA. Liver X receptors in the central nervous system: from lipid homeostasis to neuronal degeneration. Proc Natl Acad Sci USA 99: 13878-83 (2002).
73. Wellington CL, Walker EK, Suarez A, Kwok A, Bissada N, Singaraja R, et al. ABCA1 mRNA and protein distribution patterns predict multiple different roles and levels of regulation. Lab Invest 82: 273-83 (2002).
74. Whitney KD, Watson MA, Collins JL, Benson WG, Stone TM, Numerick MJ, et al. Regulation of cholesterol homeostasis by the liver X receptors in the central nervous system. Mol Endocrinol 16: 1378-85 (2002).
75. Willy PJ, Umesono K, Ong ES, Evans RM, Heyman RA and Mangelsdorf DJ. LXR, a nuclear receptor that defines a distinct retinoid response pathway. Genes Dev 9: 1033-45 (1995).
76. Wolozin B, Kellman W, Ruosseau P, Celesia GG and Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 57: 1439-43 (2000).
77. Zandi PP, Sparks DL, Khachaturian AS, Tschanz J, Norton M, Steinberg M, et al. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch Gen Psychiatry 62: 217-24 (2005).